Poolbeg Pharma PLC POLB
LSE · Vereinigtes Königreich · Gesundheitstechnologie
GBp 7,35-0,05 (-0,68 %)
Markt geschlossen· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion about the company's interim results for the first half of 2026, progress with POLB 001 and the milestones investors can expect as its clinical development programme advances. Skillington said Poolbeg Pharma made "incredible progress" during the period, successfully transitioning POLB 001 from trial preparation into active clinical development. The programme is being studied in relapsed or refractory multiple myeloma patients, aiming to prevent cytokine release syndrome associated with cancer therapy. Th
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion after a positive interim safety review of its TOPICAL clinical trial targeting cytokine release syndrome (CRS) linked to cancer therapies. The review recommended the trial continue unchanged, with recruitment ongoing at leading UK sites and further sites being activated. Skillington said the latest data adds to the preclinical evidence, previous trial data and intellectual property supporting POLB 001, while Poolbeg continues discussions with potential pharmaceutical partners. He said the focus now is o
Galliford Try (LSE:GFRD) has secured places across all five regional lots of a £9.5 billion public sector construction framework covering schools, colleges, universities and healthcare buildings across Great Britain. The framework can run for up to eight years. Poolbeg Pharma (AIM:POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 cytokine release syndrome patent, following earlier grants in Europe, Australia and Canada. The growing patent estate is expected to strengthen the drug's appeal to potential commercial partners. Tertiary Minerals (AIM:TYM) has r
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.